The National Health Service (NHS) in the UK is being pressured to accept a heart drug that could cost £2 a day onto its list for the treatment of atrial fibrillation.

About 6,000 people in Britain are affected by an abnormal heartbeat.

Dronedarone is the first new drug that has been released for 25 years designed to treat the condition, but the National Institute for Health and Clinical Excellence (NICE), which approves UK drugs, turned it down.

It said the drug was not as efficient and almost twice as expensive as some other treatments.

Some treatments cost just £2 a month, according to NICE.

Patient organisations, however, have said that many of these drugs are out of patent, and that the costs for treatment far outweighed those impacting the health service for the treatment of stroke.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

It is estimated that 16,000 patients with the condition have a stroke each year.